Merck & Co. Inc. sell melinda
Start price
26.10.21
/
50%
€70.76
Target price
26.10.22
€65.00
Performance (%)
38.64%
End price
27.10.22
€98.10
Summary
This prediction ended on 27.10.22 with a price of €98.10. The price for Merck & Co. Inc. massively increased, which is bad news for the SELL prediction by melinda. A total of €2.59 was paid as dividends for this prediction. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merck & Co. Inc. | -1.186% | -1.186% | 15.875% | -0.596% |
| iShares Core DAX® | -5,87 % | -2,50 % | 2,29 % | 50,13 % |
| iShares Nasdaq 100 | 1,66 % | 3,51 % | 13,19 % | 88,48 % |
| iShares Nikkei 225® | -6,13 % | 2,14 % | 27,67 % | 53,97 % |
| iShares S&P 500 | 0,50 % | 2,05 % | 9,82 % | 60,03 % |
According to melinda what are the pros and cons of Merck & Co. Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Merck & Co. Inc. diskutieren
Sell mit Kursziel 65,0
In the thread Trading Merck & Co. Inc.
Die von melinda gewählte maximale Laufzeit wurde überschritten
Stopped prediction by melinda for Merck & Co. Inc.
Merck & Co. Inc.
Start price
Target price
Perf. (%)
€71.50
01.03.19
01.03.19
€77.00
04.11.21
04.11.21
-1.04%
26.10.21
26.10.21
Could be worthwhile Investment >10% per year
Merck & Co. Inc.
Start price
Target price
Perf. (%)
€57.58
20.10.17
20.10.17
€59.53
20.04.18
20.04.18
-6.62%
20.04.18
20.04.18
Could be worthwhile Investment >10% per year
Merck & Co. Inc.
Start price
Target price
Perf. (%)
€63.84
20.10.17
20.10.17
€66.00
20.04.18
20.04.18
-6.62%
20.04.18
20.04.18
Could be worthwhile Investment >10% per year
Merck & Co. Inc.
Start price
Target price
Perf. (%)
€56.64
21.07.17
21.07.17
€59.53
14.09.17
14.09.17
5.90%
14.09.17
14.09.17
Could be worthwhile Investment >10% per year
Merck & Co. Inc.
Start price
Target price
Perf. (%)
€62.79
21.07.17
21.07.17
€66.00
14.09.17
14.09.17
5.90%
14.09.17
14.09.17
Could be worthwhile Investment >10% per year


